Brokers Set Expectations for Neurogene FY2026 Earnings

Neurogene Inc. (NASDAQ:NGNE) – Investment analysts at HC Wainwright upped their FY2026 earnings per share (EPS) estimates for shares of Neurogene in a report issued on Tuesday, November 10th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($5.04) per share for the year, up from their previous forecast of ($5.44). HC Wainwright currently has a “Buy” rating and a $60.00 target price on the stock. The consensus estimate for Neurogene’s current full-year earnings is ($5.78) per share. HC Wainwright also issued estimates for Neurogene’s Q4 2026 earnings at ($1.16) EPS, Q1 2027 earnings at ($1.18) EPS, Q2 2027 earnings at ($1.19) EPS, Q3 2027 earnings at ($1.21) EPS, Q4 2027 earnings at ($1.22) EPS and FY2027 earnings at ($4.80) EPS.

Neurogene (NASDAQ:NGNE) last issued its quarterly earnings data on Monday, November 9th. The company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.31.

Several other research firms have also issued reports on NGNE. Guggenheim increased their target price on shares of Neurogene from $69.00 to $81.00 and gave the stock a “buy” rating in a report on Wednesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research report on Thursday, October 15th. JPMorgan Chase & Co. began coverage on Neurogene in a research report on Thursday, October 8th. They issued an “overweight” rating and a $60.00 price objective on the stock. Canaccord Genuity Group dropped their price objective on Neurogene from $180.00 to $166.00 and set a “buy” rating for the company in a research note on Wednesday, August 12th. Finally, William Blair upgraded Neurogene to a “strong-buy” rating in a research report on Wednesday, September 23rd. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $79.57.

Neurogene Price Performance

Shares of NGNE stock opened at $25.10 on Thursday. The firm has a fifty day moving average price of $28.78 and a 200-day moving average price of $28.04. The company has a market cap of $519.60 million, a price-to-earnings ratio of -4.93 and a beta of 1.75. Neurogene has a 1 year low of $15.93 and a 1 year high of $43.66.

Institutional Investors Weigh In On Neurogene

Hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp bought a new stake in shares of Neurogene during the 2nd quarter worth approximately $904,000. BlackRock Inc. bought a new stake in Neurogene during the 2nd quarter valued at $33,274,000. Renaissance Technologies LLC increased its holdings in shares of Neurogene by 210.0% in the 1st quarter. Renaissance Technologies LLC now owns 43,400 shares of the company’s stock valued at $875,000 after acquiring an additional 29,400 shares during the period. Wellington Management Group LLP bought a new position in shares of Neurogene in the 2nd quarter worth $987,000. Finally, Deutsche Bank AG bought a new position in shares of Neurogene in the 2nd quarter worth $3,354,000. Hedge funds and other institutional investors own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene Inc. is a clinical-stage biotechnology company developing genetic medicines for rare neurological diseases. Its work focuses on using gene therapy to address the underlying causes of disorders with limited treatment options. The company’s lead program, NGN-401, is an investigational gene therapy for Rett syndrome, a rare genetic disorder that primarily affects girls and can cause significant developmental and neurological challenges. Neurogene is also advancing a broader pipeline of potential genetic medicines for rare diseases.